AML Hub
16 episodes - English - Latest episode: 8 days ago -The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
Homepage Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
What were your highlights from ASH 2023?
April 29, 2024 15:03 - 3 minutes - 18.2 MBDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. See acast.com/privacy for more information.
What are the challenges associated with CAR T-cell therapy in patients with AML?
April 25, 2024 09:05 - 9 minutes - 12.8 MBDuring the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML? Hosted on Acast. See acast.com/privacy for more information.
How might the MORPHO trial of gilteritinib impact clinical practice?
April 08, 2024 15:16 - 7 minutes - 37.6 MBThe AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice? Hosted on Acast. See acast.com/privacy for more information.
Risk stratification and guidelines in AML management
January 08, 2024 17:14 - 11 minutes - 195 MBThe AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acute myeloid leukemia (AML) management. Firstly, Roboz and Daver discuss the impact of blast count on the diagnosis of AML and how a patient's mutational profile can affect treatment decisions. They highlight available, effective lower-intensity and targeted therapies and a potential transition ...
How are new fludarabine conditioning combinations impacting transplant outcomes?
April 22, 2022 11:42 - 6 minutes - 8.35 MBDuring the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes? Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavrii...
Should pre-transplant MRD be used to guide treatment in AML?
July 10, 2021 13:00 - 6 minutes - 5.64 MBDuring the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML? Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the result of his study presented at EHA2021. Finally, he outlines the current treatment landscape fo...
Can HMA maintenance therapy improve eligibility for HSCT?
March 17, 2021 12:12 - 5 minutes - 5.08 MBDuring the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT? Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hemat...
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?
February 02, 2021 18:23 - 16 minutes - 14.8 MBDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospital & Monash University, Melbourne, AU. We asked, Does sorafenib plus intensive chemotherapy improve outcome in FLT3-internal tandem duplication (FLT3-ITD) AML? Wei starts by introducing the clinical study data from AMLM16, a randomized, placebo-controlled trial evaluating sorafenib versus placebo in c...
Venetoclax combinations in mutant AML subtypes: IDH1/2
January 25, 2021 13:41 - 6 minutes - 6.16 MBDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax combinations in patients with AML with IDH1/2 mutations. Clinical studies evaluating the combination of venetoclax + azacitidine versus azacitidine alone have shown that patients with AML with IDH1/2 mutations treated with venetoclax + azacitidine achieved higher response rates, and had better outcome...
Venetoclax combinations in mutant AML subtypes podcast: FLT3
January 20, 2021 17:11 - 12 minutes - 11.1 MBDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML. Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML. In this podcast, Daver discusses the results of a study comparing the combination of azacitidin...
Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML
January 20, 2021 17:08 - 8 minutes - 7.93 MBDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combinations in mutation subtypes of AML. In this podcast, DiNardo gives an overview of the studies on venetoclax combinations presented at ASH 2020, especially venetoclax plus azacitidine, in mutation subtypes of AML. DiNardo focuses on three specific subgroups: patients with IDH1/2 mutations; pat...
How close are we to offering treatment tailored to mutational profile?
July 08, 2020 13:16 - 5 minutes - 5.67 MBDuring the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile. Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to d...
Approaches and emerging therapies for TP53 AML
July 01, 2020 09:26 - 14 minutes - 13.3 MBDuring the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Houston, US, about novel approaches and emerging therapies for TP53 AML. Identification of disease-driving genetic aberrations has allowed for major advancements in the AML setting. TP53 mutations are observed in around 15% of patients with AML, with distinct patterns between patient subsets. Despite t...
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
June 24, 2020 16:29 - 24 minutes - 22.5 MBDuring the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the AML Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft-versus-host-disease? In this podcast, Dr Davar starts by providing a background on the importance of the...
Can CD47 antibody therapy be safely used for AML and MDS?
June 22, 2020 13:58 - 14 minutes - 13.4 MBDuring the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US. The question was, Is CD47-directed antibody therapy safe and effective in patients with AML and myelodysplastic syndromes? CD47 is a dominant negative immune checkpoint expressed by cancer cells, which facilitates immune evasion by decreasing recognit...
How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?
June 09, 2020 14:19 - 20 minutes - 18.6 MBDuring the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State University, Columbus, US and Abhay Singh from Roswell Park Comprehensive Cancer Center, Buffalo, US. This podcast discusses how the type of prior treatment can affect the risk of therapy-related myeloid neoplasms. The group start by discussing the problems clinicians face when deciding treatment plans...